Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate osmotic release oral system
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Oral
01
Overview
Osmotic release methylphenidate refers to a specific extended-release formulation of the stimulant medication methylphenidate that uses an Osmotic Release Oral System (OROS) technology. This delivery system provides both an immediate-release and a controlled extended-release phase. Upon ingestion, about 22% of the dose is released immediately for rapid onset of action; the remaining 78% is gradually released over 10–12 hours via an osmotically driven push mechanism through a laser-drilled orifice in the tablet[1][3][4]. The primary indication for this drug is attention-deficit hyperactivity disorder (ADHD) in children and adults[2][4]. Methylphenidate acts mainly as a norepinephrine-dopamine reuptake inhibitor (NDRI), blocking dopamine transporter and norepinephrine transporter to increase synaptic concentrations of these neurotransmitters in the central nervous system[6][8]. The original developer of this technology was ALZA Corporation.
- Brand names
- ConcertaRelexxiiAdhansia XR
- Other names
- osmotic release methylphenidateosmotic-controlled release oral delivery system methylphenidateOROS-methylphenidate
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on methylphenidate osmotic release oral system.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate osmotic release oral system.